BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Skull Clamp Device Market – Forecast to 2030,’ thoroughly examines the Skull Clamp Device industry to provide essential data & information for the targeted readers.

The growth in the metagenomic sequencing market has been owing to numerous factors. The market growth is generally attributed to the constant technological innovations in the NGS platforms.

Hematology is defined as the diagnostic classification of cells present in the blood and resulting identification of diseases of the blood-forming organs and diseases of the blood.

According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017. It is projected to expand at a CAGR of 11.4% from 2018 to 2026.

Radiology has emerged as a significant tool for diagnosis of several diseases and has played an extremely powerful role in the supervision of treatment and prediction of the outcome.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the reconvened Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) meeting to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS).

The increasing need for improving patient care and reducing treatment costs is a primary factor augmenting the growth of global artificial intelligence in the diagnostics market.

Medigen, Inc. announced that it is doubling the amount of space leased at Riverside Technology Park in Frederick, Maryland to 12,000 square feet, which represents the second time the biotech company has expanded its operations at 8420 Gas House Pike within the last 36 months.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of ORKAMBI® (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24 months who are homozygous for the F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

RushNet, Inc, is pleased to announce that heliosDX will absorb Grandeza Healthcare in preparation for the spinout from Rushnet.